Radius Planning Pivotal Trial of Cannabidiol RAD011

Radius Planning Pivotal Trial of Cannabidiol RAD011
0
(0)

Radius Health has acquired the development and commercialization rights to a synthetic oral cannabidiol therapy known as RAD011, with plans to start a pivotal Phase 2/3 clinical trial in Prader-Willi syndrome (PWS) this year.

Having finalized its acquisition deal with Benuvia Therapeutics, the company expects to initiate the trial in the second half of 2021 following discussions with the U.S. Food and Drug Administration (FDA).

“RAD011 has the potential for broad clinical applicability. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course,” Kelly Martin, CEO of Radius, said in a press release.

Under the agreement, Radius acquired rights to RAD011 for $12.5 million, with an additional $15 million payment contingent on successfully meeting milestones in PWS development. The therapy is part of an orphan drug program in which PWS is the first indication. Orphan drugs are therapies developed to treat rare diseases that, without special status and incentives from the government, would be unprofitable to produce. 

PWS is characterized by poor muscle tone and growth, and by hyperphagia (excessive appetite), weight gain, behavioral problems, and intellectual disability in childhood.

As a cannabidiol — an active chemical of the cannabis plant, devoid of mind-altering effects — RAD011 functions by targeting multiple signaling pathways and receptors involved in regulating hyperphagia and anxiety, the symptoms often ranked as the two most significant by caregivers of PWS patients, according to Radius. Benefits in behavioral problems also may be achieved, the company stated.

“Currently, there is no treatment for Prader-Willi syndrome. For many patients with the disorder, ameliorating some of the most difficult symptoms, such as insatiable appetite and anxiety, would be life-changing for them and their families,” said Lynne M. Bird, MD, medical director of the PWS Clinic at Rady Children’s Hospital.

Early data from an abbreviated Phase 2 clinical trial of RAD011 indicated that the treatment may help reduce hyperphagia and weight. 

The design of the upcoming trial of RAD011 will be informed by findings from previous clinical studies conducted in the PWS patient population. Top-line data could be released within about two years after the study begins, according to Radius.

The FDA granted RAD011 fast track designation in 2017 and orphan drug designation in 2020 for the treatment of hyperphagia and weight loss in PWS. Both designations convey financial and regulatory incentives for clinical development.

Aisha Abdullah received a B.S. in biology from the University of Houston and a Ph.D. in neuroscience from Weill Cornell Medical College, where she studied the role of microRNA in embryonic and early postnatal brain development. Since finishing graduate school, she has worked as a science communicator making science accessible to broad audiences.
Total Posts: 12

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×
Aisha Abdullah received a B.S. in biology from the University of Houston and a Ph.D. in neuroscience from Weill Cornell Medical College, where she studied the role of microRNA in embryonic and early postnatal brain development. Since finishing graduate school, she has worked as a science communicator making science accessible to broad audiences.
Latest Posts
  • CBD RAD011
  • pitolisant, study sites open
  • BPL-1 study

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?